845626-57-5
845626-57-5
Chemical Structure
DNA31
- CAS No.: 845626-57-5
- Formula:C48H58N4O13
- Molecular Weight:898.99
InChIKey: AOQUTNZVKHWNHJ-HXHYCRMMSA-N
SMILES: O=C1C2=C(O[C@@]1(O/C=C\[C@]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@@H](O)[C@@H](C)/C=C/C=C(C)/C3=O)C)O)C)OC(C)=O)C)([H])OC)C)C(C)=C(O)C4=C2C(C(OC5=CC(N6CCC(N)CC6)=C7)=C(N3)C4=O)=NC5=C7O
Biological Activity: DNA31 is a potent RNA polymerase inhibitor[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DNA31 | 96.21% | DNA31 is a potent RNA polymerase inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rifalazil (Standard) | ≥98% | Rifalazil (Standard) is the analytical standard of Rifalazil. This product is intended for research and analytical applications. Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MC-VC-PABC-DNA31 | 97.45% | MC-VC-PABC-DNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using DNA31 (a potent RNA polymerase inhibitor), linked via the ADC linker MC-VC-PABC. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MC-Val-Cit-PAB-dimethylDNA31 | 99.58% | MC-Val-Cit-PAB-dimethylDNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
dmDNA31 | 98.64% | dmDNA31 is a rifamycin-class antibiotic that inhibits bacterial DNA-dependent RNA polymerase with potent bactericidal activity against S. aureus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rifaximin (Standard) | ≥98% | Rifaximin (Standard) is the analytical standard of Rifaximin. This product is intended for research and analytical applications. Rifaximin, a gastrointestinal-selective antibiotic, binds the β-subunit of bacterial DNA-dependent RNA polymerase, resulting in inhibition of bacterial RNA synthesis. Rifaximin susceptibility is higher against Gram-positive strains (MIC: 0.03-5 mg/ml) compared to Gram-negative bacteria (MIC: 8-50 mg/mL). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rifaximin-d6 | 97.38% | Rifaximin-d6 is the deuterium labeled Rifaximin. Rifaximin is an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RNA polymerase-IN-1 | RNA polymerase-IN-1 (compound 4) is s DNA-dependent RNA polymerase inhibitor. RNA polymerase-IN-1 inhibits CYP isozymes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RNA polymerase-IN-2 | RNA polymerase-IN-2 (compound 5) is s DNA-dependent RNA polymerase inhibitor. RNA polymerase-IN-2 inhibits CYP isozymes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rifampicin impurity 4 | Rifampicin impurity 4 is an impurity of Rifampicin. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rifampicin impurity 3 | Rifampicin impurity 3 is an impurity of Rifampicin. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
